Moderna and Merck report Phase 2b mRNA cancer vaccine met primary endpoint in melanoma, reducing recurrence risk by 44%

Moderna, Inc.

mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.
First randomized trial evidence for an mRNA cancer treatment; companies plan Phase 3 in melanoma in 2023 and expansion to other tumor types.
Serious treatment-related AEs: 14.4% in combination arm vs 10% with KEYTRUDA alone.
Merck and Moderna share costs and profits equally under worldwide collaboration announced in October.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.